Olaparib Potentiates 177 Lu-PSMA-617 Radioligand Therapy in Prostate Cancer through Glycolytic Suppression (EANM 2026) - Sep 29, 2026 - Abstract #OP-481; Pres time: Oct 19, 2026; 04:45 PM - 06:15 PM; Location: Hall E2; "Olaparib potentiates 177Lu-PSMA-617 radioligand therapy in prostate cancer. Multi-level evidence supports glycolytic suppression as a mechanistic contributor and a potential biomarker or therapeutic vulnerability for combination RLT. These findings highlight PARP inhibition as a promising strategy to enhance PSMA-targeted radioligand therapy and provide a strong rationale for further translational evaluation of PARP inhibition to improve radioligand therapy outcomes."
Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • HRD • RAD51
|
|
Q. Wu 1, 2; L. Luo 3; R. P. Baum 4; J. Zhang 1, 2, 5
|